AU2001244088A1 - Condensed imidazoles as histamine h3 receptor ligands - Google Patents

Condensed imidazoles as histamine h3 receptor ligands

Info

Publication number
AU2001244088A1
AU2001244088A1 AU2001244088A AU4408801A AU2001244088A1 AU 2001244088 A1 AU2001244088 A1 AU 2001244088A1 AU 2001244088 A AU2001244088 A AU 2001244088A AU 4408801 A AU4408801 A AU 4408801A AU 2001244088 A1 AU2001244088 A1 AU 2001244088A1
Authority
AU
Australia
Prior art keywords
histamine
receptor ligands
condensed imidazoles
imidazoles
condensed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001244088A
Inventor
Knud Erik Andersen
Florencio Zaragoza Dorwald
Birgitte Eriksen
Rudolf Hurnaus
Bernd Krist
Stephan Georg Muller
Bernd Pesche
Klaus Rudolf
Ulla Grove Sidelmann
Dirk Stenkamp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Novo Nordisk AS
Original Assignee
Boehringer Ingelheim International GmbH
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH, Novo Nordisk AS filed Critical Boehringer Ingelheim International GmbH
Publication of AU2001244088A1 publication Critical patent/AU2001244088A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2001244088A 2000-03-17 2001-03-16 Condensed imidazoles as histamine h3 receptor ligands Abandoned AU2001244088A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200000441 2000-03-17
DKPA200000441 2000-03-17
DKPA200001016 2000-06-29
DKPA200001016 2000-06-29
PCT/DK2001/000188 WO2001068652A1 (en) 2000-03-17 2001-03-16 Condensed imidazoles as histamine h3 receptor ligands

Publications (1)

Publication Number Publication Date
AU2001244088A1 true AU2001244088A1 (en) 2001-09-24

Family

ID=26068796

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001244088A Abandoned AU2001244088A1 (en) 2000-03-17 2001-03-16 Condensed imidazoles as histamine h3 receptor ligands

Country Status (4)

Country Link
EP (1) EP1268484A1 (en)
JP (1) JP2003527395A (en)
AU (1) AU2001244088A1 (en)
WO (1) WO2001068652A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002356525A1 (en) * 2001-09-24 2003-04-07 Elan Pharmaceuticals, Inc. Substituted amines for the treatment of neurological disorders
WO2003049702A2 (en) 2001-12-10 2003-06-19 Amgen Inc. Vanilloid receptor ligands and their use in treatments
EP1780196A3 (en) * 2001-12-10 2007-05-09 Amgen, Inc Pyridine derivatives for use as vanilloid receptor ligands
JP2003192587A (en) * 2001-12-26 2003-07-09 Bayer Ag Urea derivative
EP1388342A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7105513B2 (en) 2002-08-07 2006-09-12 Sanofi-Avertis Deutschland Gmbh Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
EP1585731A2 (en) * 2002-09-18 2005-10-19 Eli Lilly And Company Histamine h3 receptor antagonists, preparaton and therapeutic uses
WO2004112701A2 (en) * 2003-06-17 2004-12-29 Merck & Co., Inc. Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JP2007528860A (en) * 2003-07-28 2007-10-18 財団法人大阪産業振興機構 Hypoglycemic composition
SG188367A1 (en) 2010-09-03 2013-04-30 Forma Tm Llc Novel compounds and compositions for the inhibition of nampt
CN102452988B (en) 2010-10-27 2016-01-27 中国科学院化学研究所 A kind of quinazoline derivant and preparation method thereof
JP6020459B2 (en) 2011-10-18 2016-11-02 アステラス製薬株式会社 Bicyclic heterocyclic compounds
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
US20140057920A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
CN108314641B (en) * 2017-12-27 2020-11-13 阜新龙瑞药业有限责任公司 Preparation method of natural product Norpsilocin
WO2019148244A1 (en) * 2018-02-01 2019-08-08 The University Of Sydney Anti-cancer compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2004911A1 (en) * 1988-12-22 1990-06-22 Mitsuaki Ohta 4,5,6,7-tetrahydrobenzimidazole derivatives
EP0381422B1 (en) * 1989-02-02 1996-10-23 Yamanouchi Pharmaceutical Co. Ltd. Tetrahydrobenzimidazole derivatives
JPH049372A (en) * 1990-04-25 1992-01-14 Yamanouchi Pharmaceut Co Ltd 4,5,6,7-tetrahydrobenzimidazole derivative
AU7707994A (en) * 1993-09-30 1995-04-18 Tokyo Tanabe Company Limited Indoline derivative and 5-ht3 receptor antagonist containing the same as active ingredient

Also Published As

Publication number Publication date
WO2001068652A1 (en) 2001-09-20
EP1268484A1 (en) 2003-01-02
JP2003527395A (en) 2003-09-16

Similar Documents

Publication Publication Date Title
AU2002244271A1 (en) Non-imidazole compounds as histamine h3 antagonists
HK1100219A1 (en) Novel condensed imidazole derivatives
AU2002254114A1 (en) Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
MXPA03000939A (en) Imidazole derivatives.
AU2001234128A1 (en) Novel imidazoline compounds
MXPA03006773A (en) Imidazole derivatives.
IL165611A0 (en) 1H-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands
AU2001244088A1 (en) Condensed imidazoles as histamine h3 receptor ligands
AU2002259043A1 (en) Improved composite tubing
AU2002348503A1 (en) Quinuclidine-substituted heteroaromatic compounds as ligands at nicotinic acetylcholine receptors
GB0225807D0 (en) Composite packer cup
AU2001264657A1 (en) Crf receptor antagonists
MXPA03008205A (en) Process for the preparation of imidazole compounds.
AU1073501A (en) Histamine receptor
ZA200102833B (en) Organosilicon compounds.
MXPA03002446A (en) Substituted imidazoles as dual histamine h1.
AU2001244087A1 (en) Condensed imidazoles as histamine h3 receptor ligands
ZA200205301B (en) New imidazole derivatives.
AU2001263288A1 (en) Crf receptor antagonists
MXPA03002445A (en) Substituted imidazoles as dual histamine h1.
MXPA03006408A (en) Histamine receptor antagonists.
AU3324700A (en) Imidazole compounds
AUPQ515700A0 (en) Imidazole compounds
AU2002306841A1 (en) Imidazolyl derivatives useful as histamine h3 receptor ligands
AUPR636301A0 (en) Imidazole compounds